MAP2K7 and intrahepatic cholangiocarcinoma: A recent study showed via an unplanned post hoc analysis that the benefits of administering PDL1 plus MEK inhibitors were primarily observed in the subgroup of patients with ICC (Yarchoan et al., 2021b).